Quidel enlisted ICS' multidisciplinary team to be the application developer of the next-generation, fully integrated molecular diagnostic system for its Savanna platform.
The low-cost, point-of-care testing platform allows for easy rapid results for disease states and conditions such as COVID-19, MRSA and HIV.
The Savanna project started with UX design leading to an intuitive CLIA-waived touchscreen interface and an extensible processing architecture. It also includes software applications and powerful, forward-looking cybersecurity for its fleet in the field.
With Savanna, Quidel will deploy a future-proof in-vitro diagnostics platform that's flexible, scalable, configurable and secure.
In its collaboration with ICS, Quidel convenes best-practices from usability, cybersecurity, cloud and user management on an embedded touch-screen platform.
ICS has collaborated with Quidel on other point-of-care technologies, which have received Emergency Use Authorization from the US Food and Drug Administration.
ICS assisted Quidel in bringing development in-house, setting up a new continuous integration system to build the software and run automated unit tests, enabling the generation of new software releases following a development and test process that meets the stringent requirements of medical devices.
ICS also designed and implemented new product features, including an IoT-based facility for software updates and remote device management.
At the intersection of custom software development, engineering and UX design, Integrated Computer Solutions (ICS) has been helping Fortune 1000 companies create transformative products for over 30 years.
ICS is headquartered in Waltham, Mass., with offices in Sunnyvale, California and Ottawa, Ontario.
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amneal's risperidone extended-release injectable suspension approved by US FDA
Brain+ pilot shows Ayla therapy boosts cognitive outcomes in dementia care
Ascelia Pharma files NDA with FDA for liver imaging drug Orviglance
Biophytis secures EMA clearance to advance Phase 2 obesity trial
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15
Eisai begins rolling sBLA to US FDA for initiation dosing of LEQEMBI IQLIK
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
BeOne Medicines reports positive topline data for sonrotoclax in mantle cell lymphoma
Cinclus Pharma to launch Phase III trial of linaprazan glurate in erosive GERD